Drug Profile
Research programme: allergic rhinitis therapy - Topigen
Alternative Names: Allergic rhinitis therapy research programme - Topigen; ALR 8; TPI-ALR8Latest Information Update: 04 Mar 2010
Price :
$50
*
At a glance
- Originator Topigen Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic rhinitis
Most Recent Events
- 16 Dec 2004 Preclinical trials in Allergic rhinitis in Canada (Intranasal)